Pulmonary Cell News 8.28 July 25, 2019 | |
| |
TOP STORYType 1 IFN signaling via the interferon (IFN)-1 receptor was essential for acetate antiviral activity in pulmonary epithelial cell lines and for the acetate protective effect in respiratory syncytial virus-infected mice. [Nat Commun] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists found that hinesol effectively inhibited A549 and NCI-H1299 cells in a dose- and time-dependent manner by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide assay. [J Cell Biol] Abstract Enhanced Tropism of Species B1 Adenoviral-Based Vectors for Primary Human Airway Epithelial Cells Investigators screened 14 adenovirus (Ad) types representing species C, B1, B2, D, and E. Using well-differentiated primary cultures of human airway epithelial cells (HAE), they examined transduction efficiency. Based on GFP or nanoluciferase expression, multiple Ad types transduced HAE as well as or better than Ad5. [Mol Ther Methods Clin Dev] Abstract | Full Article The authors employed multiplexed stable isotope resolved metabolomics to track the metabolism of 13C6-glucose, D2-glycine, 13C2-glycine, and D3-serine into purine nucleotides in freshly resected cancerous and matched non-cancerous lung tissues from non-small cell lung cancer (NSCLC) patients and compared the metabolism with established NSCLC PC9 and A549 cell lines in vitro. [J Biol Chem] Abstract | Full Article Vanin-1 (VNN1) was verified to be targeted and negatively regulated by miR-203. In mouse models of septic shock, weak expression of miR-203, high expression of VNN1, and inhibition of AKT signaling pathway were identified. [Kidney Blood Press Res] Full Article LUNG CANCERThe CREB Coactivator CRTC2 Promotes Oncogenesis in LKB1-Mutant Non-Small Cell Lung Cancer CRTC2 was unphosphorylated and therefore constitutively activated in LKB1-mutant non-small cell lung cancer, where it promoted tumor growth, in part via the induction of the inhibitor of DNA binding 1, a bona fide cAMP response element-binding protein (CREB) target gene. [Sci Adv] Abstract | Press Release SOX7 Regulates MAPK/ERK-BIM Mediated Apoptosis in Cancer Cells Low expression of SOX7 was associated with advantage stage of cancer with shorter overall survival. Cancer cells with loss of SOX7 promoted cell survival and colony formation, suppressed cellular apoptosis and produced a drug resistant phenotype against a variety of chemo/targeting therapeutic agents. [Oncogene] Abstract Genetic ablation of interleukin-17C (Il-17c) resulted in decreased recruitment of inflammatory cells into the tumor microenvironment, a decreased expression of tumor-promoting cytokines, and reduced tumor proliferation in the presence of Haemophilus influenzae-induced COPD-like lung inflammation. [Sci Rep] Full Article Researchers investigated the role of glucosidase II beta subunit (GluIIβ) in cell growth, metastatic potential, and receptor tyrosine kinase signaling activity in lung carcinoma cell lines. CRISPR-CAS9 technology was used to knockout the GluIIβ encoding gene in lung carcinoma cells. [Sci Rep] Full Article Coxsackievirus Type B3 is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma In cultured cells, scientists discovered that coxsackievirus B3 selectively infected and lysed KRAS-mutant lung adenocarcinoma cells, while sparing normal lung epithelial cells and EGFR-mutant lung adenocarcinoma cells. [Mol Ther Oncolytics] Abstract | Full Article Subscribe to one of our other 19 science newsletters such as Cancer Stem Cell News & Human Immunology News. | |
| |
REVIEWSThe authors introduce the development and evaluation of therapeutic agents that may halt lung cancer progression via the manipulation of macrophage polarization. [J Drug Target] Abstract Visit our reviews page to see a complete list of reviews in the pulmonary cell research field. | |
| |
INDUSTRY NEWSProteostasis Therapeutics Initiates Dosing in Global Phase II Study in Cystic Fibrosis Proteostasis Therapeutics, Inc. announced that the first patient has been dosed in the company’s 28-day, Phase II study evaluating its proprietary cystic fibrosis transmembrane conductance regulator modulator combinations in F508del homozygous and heterozygous CF subjects. [Proteostasis Therapeutics, Inc.] Press Release Bristol-Myers Squibb Announces CheckMate-227 Part Ia Meets Co-Primary Endpoint of Overall Survival Bristol-Myers Squibb Company announced that Part Ia of the Phase III CheckMate-227 trial evaluating nivolumab plus low-dose ipilimumab met the co-primary endpoint of overall survival, demonstrating a superior benefit versus chemotherapy in first-line non-small cell lung cancer patients whose tumors express PD-L1 ≥1%. [Bristol-Myers Squibb Company] Press Release Bristol-Myers Squibb Provides Update on Part II of CheckMate-227 Bristol-Myers Squibb Company announced that Part II of the Phase III CheckMate-227 trial did not meet the primary endpoint of overall survival with nivolumab plus chemotherapy versus chemotherapy in patients with first-line non-squamous non-small cell lung cancer, regardless of PD-L1 status. [Bristol-Myers Squibb Company] Press Release resTORbio, Inc. announced that it has completed patient enrollment of the Phase III PROTECTOR 1 trial, ahead of previously announced clinical timelines, with 1,024 patients randomized. [resTORbio, Inc.] Press Release FibroGen, Inc. announced dosing of the first patient in the ZEPHYRUS Phase III clinical study of pamrevlumab in patients with idiopathic pulmonary fibrosis. [FibroGen, Inc.] Press Release Aridis Pharmaceuticals, Inc. announced that the European Medicines Agency has granted Orphan Drug Designation to AR-501, the company’s inhaled formulation of gallium citrate for treatment of lung infection in patients with cystic fibrosis. [Aridis Pharmaceuticals, Inc. (PR Newswire Association LLC)] Press Release | |
| |
POLICY NEWSUS scientists who challenged a new rule that would require them to register their basic studies of the human brain and behavior in a federal database of clinical trials have won another reprieve. The National Institutes of Health in Bethesda, Maryland, says it now understands why some of that kind of research won’t easily fit the format of ClinicalTrials.gov, and the agency has delayed the reporting requirements for another two years. [ScienceInsider] Editorial Indonesia’s Strict New Biopiracy Rules Could Stifle International Research Indonesia’s rich biodiversity and complex geology have lured scientists from abroad for centuries. But a law adopted by Indonesia’s parliament may convince some to go elsewhere. The legislation includes strict requirements on foreign scientists doing research in Indonesia, including the need to recruit local collaborators and a near-ban on exporting specimens, along with stiff sanctions, including jail time, for violators. [ScienceInsider] Editorial
| |
EVENTSNEW Barrier Immunity Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Scientific Communications Coordinator (STEMCELL Technologies Inc.) NEW Assistant/Associate Professor – Respiratory Tract Infections (Hannover Medical School) Scientist – Pulmonary (STEMCELL Technologies Inc.) Postdoctoral Fellowship – Lung Epithelium (Boston University) Postdoctoral Positions – Pulmonary Injury (University of Maryland) PhD Studentship – Extracellular Vesicles in Pulmonary Fibrosis (Université de Franche-Comté) Postdoctoral Position – Lung Injury (University of Connecticut) Postdoctoral Researcher – Cystic Fibrosis Stem Cell Models (The University of Alabama at Birmingham) Postdoctoral Researcher – Lung Lineage Development (Hospital for Sick Children) Assistant Professor – Lung Disease Research (University of McGill) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pulmonary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|